Focusing on the enhanced conversion of Ang II without Spike binding, such as B38-CAP or soluble ACE2 mutated not to bind Spike, might be an alternative option to treat ARDS in COVID-19 patients. The gene discussed is ACE2; the disease is COVID-19.